3SBio Inc (1530):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:3SBio Inc (1530) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10004
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:40
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:中国
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
3SBio Inc (3SBio) is a biotechnology companies that carries out the research, development, manufacturing and marketing of biopharmaceutical products. It develops recombinant, or genetically engineered, protein-based products and other pharmaceutical product candidates to address large markets with significant unmet medical needs in the areas of cancer and its supportive care, nephrology, dermatology and other therapeutic areas. the company’s products are distributed to hospitals, clinics and dialysis centers across China. The company’s products are approved for sale in Colombia, Brazil, Costa Rica, Egypt, Dominican Republic, Guatemala, El Salvador, Mongolia, Laos, Pakistan, Sri Lanka, Myanmar, Philippines, Paraguay, Thailand and Trinidad and Tobago. 3SBio is headquartered in Shenyang, China.

3SBio Inc (1530) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
3SBio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
3SBio Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
3SBio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
3SBio Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
3SBio Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
3SBio Inc, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
3SBio Acquires Anti-TNF Monoclonal Antibody Technology from Apexigen 11
3SBio Acquires Patents For DJ5, Potential Renal Failure Therapy, From SIMM 12
Venture Financing 13
Refuge Biotech Raises USD25 Million in Series B Financing 13
Private Equity 15
3SBio CEO And Citic Private Equity Funds Complete Acquisition Of 3SBio 15
Partnerships 17
Refuge Biotechnologies Enters into Agreement with 3SBio 17
3SBio and CPE Funds to Form Joint Venture 18
3SBio Enters into Distribution Agreement with Eli Lilly 19
TNK Therapeutics to Form Joint Venture with Shenyang Sunshine Pharma 20
3SBio Enters Into Strategic Alliance with Ascentage Pharma 21
3SBio Enters Into Joint Venture Agreement With DaVita For Dialysis Treatment 22
Licensing Agreements 23
3SBio Enters into Licensing Agreement with Alteogen 23
3SBio Enters into Licensing Agreement with PharmAbcine for DIG-KT 24
3SBio Enters into Licensing Agreement with PharmAbcine for Tanibirumab 25
3SBio Enters into Licensing Agreement with JenKem for PEG-Irinotecan 26
3SBio Enters into Licensing Agreement with DiNonA for Leukotuximab 27
Selecta Biosciences Enters into Licensing Agreement with 3SBio for Pegsiticase 28
Equity Offering 29
3SBio Completes Private Placement 29
3SBio Raises USD569 Million in IPO 30
Acquisition 31
3SBio Acquires 47% Stake in Shanghai CP Guojian Pharma for USD214 Million 31
3SBio Acquires Zhejiang Wansheng Pharma for USD86 Million 32
3SBio Acquires Sciprogen 33
3SBio Acquires Sirton Pharma 34
3SBio Inc – Key Competitors 35
3SBio Inc – Key Employees 36
3SBio Inc – Locations And Subsidiaries 37
Head Office 37
Other Locations & Subsidiaries 37
Recent Developments 39
Corporate Communications 39
Jan 09, 2017: 3SBio Appoints Dr. Zhenping Zhu as President of Research & Development and Chief Scientific Officer 39
Appendix 40
Methodology 40
About GlobalData 40
Contact Us 40
Disclaimer 40

List of Tables
3SBio Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
3SBio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
3SBio Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
3SBio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
3SBio Inc, Deals By Therapy Area, 2012 to YTD 2018 8
3SBio Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
3SBio Acquires Anti-TNF Monoclonal Antibody Technology from Apexigen 11
3SBio Acquires Patents For DJ5, Potential Renal Failure Therapy, From SIMM 12
Refuge Biotech Raises USD25 Million in Series B Financing 13
3SBio CEO And Citic Private Equity Funds Complete Acquisition Of 3SBio 15
Refuge Biotechnologies Enters into Agreement with 3SBio 17
3SBio and CPE Funds to Form Joint Venture 18
3SBio Enters into Distribution Agreement with Eli Lilly 19
TNK Therapeutics to Form Joint Venture with Shenyang Sunshine Pharma 20
3SBio Enters Into Strategic Alliance with Ascentage Pharma 21
3SBio Enters Into Joint Venture Agreement With DaVita For Dialysis Treatment 22
3SBio Enters into Licensing Agreement with Alteogen 23
3SBio Enters into Licensing Agreement with PharmAbcine for DIG-KT 24
3SBio Enters into Licensing Agreement with PharmAbcine for Tanibirumab 25
3SBio Enters into Licensing Agreement with JenKem for PEG-Irinotecan 26
3SBio Enters into Licensing Agreement with DiNonA for Leukotuximab 27
Selecta Biosciences Enters into Licensing Agreement with 3SBio for Pegsiticase 28
3SBio Completes Private Placement 29
3SBio Raises USD569 Million in IPO 30
3SBio Acquires 47% Stake in Shanghai CP Guojian Pharma for USD214 Million 31
3SBio Acquires Zhejiang Wansheng Pharma for USD86 Million 32
3SBio Acquires Sciprogen 33
3SBio Acquires Sirton Pharma 34
3SBio Inc, Key Competitors 35
3SBio Inc, Key Employees 36
3SBio Inc, Other Locations 37
3SBio Inc, Subsidiaries 37

List of Figures
3SBio Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
3SBio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
3SBio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
3SBio Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
3SBio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
3SBio Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
3SBio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
3SBio Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[3SBio Inc (1530):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Blue Nile, Inc.:企業の戦略・SWOT・財務情報
    Blue Nile, Inc. - Strategy, SWOT and Corporate Finance Report Summary Blue Nile, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • VEON LTD. (VIP):企業の財務・戦略的SWOT分析
    VEON LTD. (VIP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Edison SpA (EDNR):電力:M&Aディール及び事業提携情報
    Summary Edison SpA (Edison), a subsidiary of Electricite de France S.A., is an energy company that explores, produces, develops and sells natural gas and crude oil in the Mediterranean Basin. The company generates and sells electricity; and develops, stores, transports and sells gas in Italy. Edison …
  • Ergomed Plc (ERGO):企業の財務・戦略的SWOT分析
    Summary Ergomed Plc (Ergomed), formerly Ergomed Clinical Research Ltd, is a drug development and clinical research services provider. The company provides various services such as regulatory and quality management, biostatistics, study management, clinical data management, medical writing, and other …
  • Zayo Group Holdings Inc (ZAYO):企業の財務・戦略的SWOT分析
    Zayo Group Holdings Inc (ZAYO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Maersk Line AS:企業の戦略的SWOT分析
    Maersk Line AS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • Best Western International Inc:企業の戦略・SWOT・財務情報
    Best Western International Inc - Strategy, SWOT and Corporate Finance Report Summary Best Western International Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • State Atomic Energy Corporation Rosatom:電力:M&Aディール及び事業提携情報
    Summary State Atomic Energy Corporation Rosatom (ROSATOM) is the Russian Federation national nuclear corporation. It provides a wide range of services in the nuclear production chain, from uranium exploration and mining, uranium conversion and enrichment, nuclear fuel fabrication, mechanical enginee …
  • Brunei National Petroleum Co Sdn Bhd:石油・ガス:M&Aディール及び事業提携情報
    Summary Brunei National Petroleum Co Sdn Bhd (PetroleumBRUNEI) is an oil and gas company that provides exploration and production of oil and gas. The company offers engineering, procurement, construction, installation, commissioning services, and others. It provides oilfield services, onshore and of …
  • Boston Pharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Boston Pharmaceuticals Inc (Boston Pharma) is a drug development company that develops new drugs for unmet needs. The company acquires and advances various drug candidates from investigational new drug application (IND) through Phase 2 including BOS161721, BOS172767, BOS173717, BOS172722, BO …
  • Walchandnagar Industries Ltd
    Walchandnagar Industries Ltd - Strategy, SWOT and Corporate Finance Report Summary Walchandnagar Industries Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • LG Life Science LTD (068870)-製薬・医療分野:企業M&A・提携分析
    Summary LG Life Science LTD (LGLS) is a global life science company that offers development, production and marketing of pharmaceutical products. The company provides pipeline of antibiotic, Factive and other drug candidates. Its products include vaccines, anti-infective, chemicals, veterinary medic …
  • PG&E Corp:企業の発電所・SWOT分析2018
    PG&E Corp - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees (executiv …
  • BG Medicine Inc:医療機器:M&Aディール及び事業提携情報
    Summary BG Medicine Inc (BGM), formerly Beyond Genomics Inc is a medical device company that discovers, develops and delivers diagnostic products. The company offers diagnostis products to aid in the clinical management of heart failure and related disorders. It offers BGM Galectin-3 test, an in vit …
  • Ingles Markets Inc:企業の戦略・SWOT・財務分析
    Ingles Markets Inc - Strategy, SWOT and Corporate Finance Report Summary Ingles Markets Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Distil plc:企業の戦略・SWOT・財務情報
    Distil plc - Strategy, SWOT and Corporate Finance Report Summary Distil plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • ENN Energy Holdings Ltd (2688):石油・ガス:M&Aディール及び事業提携情報
    Summary ENN Energy Holdings Ltd (ENN) is a clean energy distributor that offers sales and distribution of piped gas, LNG and other energy products. The company conducts investment, operation and management of gas pipeline infrastructure, wholesale of gas, the sales, distribution of piped gas and oth …
  • Stantec Inc (STN)-石油・ガス分野:企業M&A・提携分析
    Summary Stantec Inc. (Stantec) is a consulting services company offering architectural, engineering, and environmental services. Its service portfolio includes architecture and interior design, building engineering, community design services, geomatics, geotechnical engineering, landscape architectu …
  • Edinburgh Molecular Imaging Ltd:企業の製品パイプライン分析2018
    Summary Edinburgh Molecular Imaging Ltd (EM Imaging) is a biotechnology company that develops optical molecular imaging technology. The company offers discovery and development of small molecules and peptides. It designs agents to improve the diagnosis and treatment of cancer and lung diseases. EM I …
  • ZAPPALLAS, Inc. (3770):企業の財務・戦略的SWOT分析
    ZAPPALLAS, Inc. (3770) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆